Vanberra Signal

Prevencio

Curated by Signal

Protein-based diagnostics for cardiovascular diseases

Overview

Prevencio develops protein-based diagnostics and prognostic solutions for cardiovascular diseases. Its flagship assay HART uses proteomics to diagnose coronary artery disease (CAD). Additionally, the test uses protein signatures to determine the risk of myocardial infarction, stroke or cardiovascular death within a year for patients diagnosed with CAD.

Key facts

Founded
2006

Business model

Contact

Open roles

1 role
  • Senior Clinical Research Associate / Clinical Research Manager

    United States · On-site · Volunteer

More on Vanberra Signal

Members only

Competitors & similar companies

More Life Sciences Technology companies
  • Developer of a technology platform for directed evolution of proteins and various applications

    Life Sciences TechnologyVacaville, United States
  • Blood glucose monitoring system and app

    Life Sciences TechnologyParsippany Troy Hills, United States
  • Developer of software for genome sequence analysis

    Life Sciences TechnologyChino Hills, United States

About Prevencio

What does Prevencio do?

Prevencio develops protein-based diagnostics and prognostic solutions for cardiovascular diseases.

Where is Prevencio headquartered?

Prevencio is headquartered in Kirkland, United States.

When was Prevencio founded?

Prevencio was founded in 2006.

Which sector is Prevencio in?

Prevencio operates in Life Sciences Technology.

Who are Prevencio's competitors?

Companies similar to Prevencio include Novici Biotech, Contour Next, and JPA Scientific.

Is Prevencio hiring?

Yes. Prevencio has 1 open role listed on Vanberra Signal.